- Home
- UCAR vs SABS Comparison
UCAR vs SABS Comparison
Compare UCAR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- SABS
- Stock Information
- Founded
- UCAR 2013
- SABS 2014
- Country
- UCAR China
- SABS United States
- Employees
- UCAR N/A
- SABS N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- SABS Health Care
- Exchange
- UCAR Nasdaq
- SABS Nasdaq
- Market Cap
- UCAR 26.6M
- SABS 23.9M
- IPO Year
- UCAR 2023
- SABS N/A
- Fundamental
- Price
- UCAR $6.44
- SABS $3.11
- Analyst Decision
- UCAR
- SABS Strong Buy
- Analyst Count
- UCAR 0
- SABS 5
- Target Price
- UCAR N/A
- SABS $12.40
- AVG Volume (30 Days)
- UCAR 24.6K
- SABS 82.3K
- Earning Date
- UCAR 10-08-2024
- SABS 11-06-2024
- Dividend Yield
- UCAR N/A
- SABS N/A
- EPS Growth
- UCAR N/A
- SABS N/A
- EPS
- UCAR N/A
- SABS N/A
- Revenue
- UCAR $4,273,899.00
- SABS $1,512,723.00
- Revenue This Year
- UCAR N/A
- SABS N/A
- Revenue Next Year
- UCAR N/A
- SABS N/A
- P/E Ratio
- UCAR N/A
- SABS N/A
- Revenue Growth
- UCAR 473.55
- SABS N/A
- 52 Week Low
- UCAR $4.21
- SABS $2.16
- 52 Week High
- UCAR $211.00
- SABS $9.72
- Technical
- Relative Strength Index (RSI)
- UCAR 39.75
- SABS 48.33
- Support Level
- UCAR $6.20
- SABS $3.00
- Resistance Level
- UCAR $6.79
- SABS $3.74
- Average True Range (ATR)
- UCAR 0.49
- SABS 0.44
- MACD
- UCAR -0.16
- SABS -0.07
- Stochastic Oscillator
- UCAR 8.26
- SABS 7.66
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufactory and sales; battery swapping services and sourcing services. The company as a broker engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.